BioCentury
ARTICLE | Financial News

Nextech leads Revolution Medicines' $56M series B

April 24, 2018 1:59 PM UTC

Revolution Medicines Inc. (Redwood City, Calif.) raised $56 million in a series B round led by new investor Nextech Invest, with participation by new investors Casdin Capital and Schroder Adveq and existing investors The Column Group and Third Rock Ventures.

This year, the company plans to start a clinical trial of lead candidate RMC-4630, a Src homology protein tyrosine phosphatase 2 (SHP-2; SHPTP2; PTPN11) inhibitor to treat solid tumors...